Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, Hemminki O, Diaconu I, Pesonen S, Koski A, Kangasniemi L, Pesonen SK, Oksanen M, Laasonen L, Partanen K, Joensuu T, Zhao F, Kanerva A, Hemminki A. Liikanen I, et al. Among authors: diaconu i. Mol Ther. 2013 Jun;21(6):1212-23. doi: 10.1038/mt.2013.51. Epub 2013 Apr 2. Mol Ther. 2013. PMID: 23546299 Free PMC article.
Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Rantanen V, Eriksson M, Hakkarainen T, Lusky M, Erbs P, Escutenaire S, Kanerva A, Pesonen S, Cerullo V, Hemminki A. Dias JD, et al. Among authors: diaconu i. Clin Cancer Res. 2010 May 1;16(9):2540-9. doi: 10.1158/1078-0432.CCR-09-2974. Epub 2010 Apr 13. Clin Cancer Res. 2010. PMID: 20388844
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.
Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Särkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimäki A, Räisänen-Sokolowski A, Haavisto E, Oksanen M, Karli E, Karioja-Kallio A, Holm SL, Kouri M, Joensuu T, Kanerva A, Hemminki A. Cerullo V, et al. Among authors: diaconu i. Cancer Res. 2010 Jun 1;70(11):4297-309. doi: 10.1158/0008-5472.CAN-09-3567. Epub 2010 May 18. Cancer Res. 2010. PMID: 20484030
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Pesonen S, Joensuu T, Kanerva A, Hemminki A. Koski A, et al. Among authors: diaconu i. Mol Ther. 2010 Oct;18(10):1874-84. doi: 10.1038/mt.2010.161. Epub 2010 Jul 27. Mol Ther. 2010. PMID: 20664527 Free PMC article. Clinical Trial.
In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments.
Escutenaire S, Cerullo V, Diaconu I, Ahtiainen L, Hannuksela P, Oksanen M, Haavisto E, Karioja-Kallio A, Holm SL, Kangasniemi L, Ribacka C, Kauppinen S, Joensuu T, Arstila TP, Pesonen S, Kanerva A, Hemminki A. Escutenaire S, et al. Among authors: diaconu i. Ann Med. 2011 Mar;43(2):151-63. doi: 10.3109/07853890.2010.538079. Epub 2011 Jan 25. Ann Med. 2011. PMID: 21261555
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, Partanen K, Karli E, Haavisto E, Oksanen M, Karioja-Kallio A, Hannuksela P, Holm SL, Kauppinen S, Joensuu T, Kanerva A, Hemminki A. Pesonen S, et al. Among authors: diaconu i. Int J Cancer. 2012 Apr 15;130(8):1937-47. doi: 10.1002/ijc.26216. Epub 2011 Aug 8. Int J Cancer. 2012. PMID: 21630267 Free article. Clinical Trial.
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, Romano V, Rouvinen N, Tuuminen T, Laasonen L, Partanen K, Kauppinen S, Joensuu T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Kanerva A, Pesonen S, Arstila PT, Hemminki A. Cerullo V, et al. Among authors: diaconu i. Mol Ther. 2011 Sep;19(9):1737-46. doi: 10.1038/mt.2011.113. Epub 2011 Jun 14. Mol Ther. 2011. PMID: 21673660 Free PMC article. Clinical Trial.
Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.
Liikanen I, Monsurrò V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, Escutenaire S, Hemminki O, Dias JD, Cerullo V, Kanerva A, Pesonen S, Marzioni D, Colombatti M, Hemminki A. Liikanen I, et al. Among authors: diaconu i. Mol Ther. 2011 Oct;19(10):1858-66. doi: 10.1038/mt.2011.144. Epub 2011 Jul 26. Mol Ther. 2011. PMID: 21792178 Free PMC article.
58 results